{
  "id": 6898151,
  "title": "Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer",
  "url": "https://urgent.news/2026/09/12/extended-interval-tarlatamab-dosing-shows-consistent-activity-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-12T09:20:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-interval-tarlatamab-dosing-safety-previously.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung cancer (SCLC), according to results from the randomized Phase II DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}